Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TYMS | P04818 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 3/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30089426 | 1.00 | DAO (0.43) | DAOPARP1ALDH1A1LMNAPOLB | |
| SCHEMBL874689 | 0.85 | PARP1 (0.54) | DAOPARP1ALDH1A1LMNAPOLB | |
| SCHEMBL38658683 | 0.78 | METAP2 (0.43) | MAPTTYMSJAK2TNKSTNKS2 | |
| SCHEMBL10987574 | 0.78 | METAP2 (0.43) | MAPTTYMSJAK2TNKSTNKS2 | |
| SCHEMBL874742 | 0.78 | PARP1 (0.54) | PARP1ALDH1A1LMNAPOLBMAPT | |
| SCHEMBL873653 | 0.78 | ALDH1A1 (0.54) | DAOPARP1ALDH1A1LMNAPOLB | |
| SCHEMBL1843189 | 0.77 | PARP1 (0.58) | PARP1ALDH1A1MAPTKDM4ETNKS | |
| SCHEMBL1844924 | 0.77 | IP6K1 (0.33) | PARP1 | |
| SCHEMBL28953289 | 0.74 | PRMT5 (0.49) | PARP1ALDH1A1MAPTKDM4EJAK2 | |
| SCHEMBL17950683 | 0.74 | TYMS (0.40) | ALDH1A1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108276352-B | Nitrogen-containing heterocyclic compound with nematicidal activity and preparation method and application thereof | 华东理工大学 | 2022-09-20 | — | — | CN | disclosed |
| CN-104530037-B | Triazine heterocyclic compound with nematicidal activity and preparation method and application thereof | 华东理工大学 | 2020-12-18 | — | — | CN | disclosed |
| WO-2016116058-A1 | TRIAZINE HETEROCYCLIC COMPOUND WITH NEMATICIDAL ACTIVITY AND PREPARATION METHOD THEREFOR AND USAGE THEREOF | 华东理工大学 | 2016-07-28 | — | — | WO | disclosed |
| EP-2780332-B1 | MORPHOLINYLBENZOTRIAZINES FOR USE IN CANCER THERAPY | MERCK PATENT GMBH (DE) | 2016-02-24 | — | — | EP | disclosed |
| EP-2780332-B1 | MORPHOLINYLBENZOTRIAZINES FOR USE IN CANCER THERAPY | MERCK PATENT GMBH (DE) | 2016-02-24 | — | — | EP | disclosed |
| US-9187469-B2 | Morpholinylbenzotriazines for use in cancer therapy | MERCK PATENT GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187469-B2 | Morpholinylbenzotriazines for use in cancer therapy | MERCK PATENT GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187469-B2 | Morpholinylbenzotriazines for use in cancer therapy | MERCK PATENT GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| EP-2780332-A1 | MORPHOLINYL BENZOTRIAZINE FOR USE IN CANCER THERAPY | Merck Patent GmbH (DE) | 2014-09-24 | — | — | EP | disclosed |
| US-20140275072-A1 | MORPHOLINYLBENZOTRIAZINES FOR USE IN CANCER THERAPY | MERCK PATENT GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275072-A1 | MORPHOLINYLBENZOTRIAZINES FOR USE IN CANCER THERAPY | MERCK PATENT GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275072-A1 | MORPHOLINYLBENZOTRIAZINES FOR USE IN CANCER THERAPY | MERCK PATENT GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
| WO-2013072015-A1 | MORPHOLINYL BENZOTRIAZINE FOR USE IN CANCER THERAPY | MERCK PATENT GMBH (DE) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013072015-A1 | MORPHOLINYL BENZOTRIAZINE FOR USE IN CANCER THERAPY | MERCK PATENT GMBH (DE) | 2013-05-23 | — | — | WO | disclosed |
| US-4520023-A | FUNGICIDES, BACTERICIDES, ALGICIDES, SLIMICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1985-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275072-A1 | MORPHOLINYLBENZOTRIAZINES FOR USE IN CANCER THERAPY | TTBK1, TTBK2, SRMS | DAO 2575/4885PARP1 2184/4885ALDH1A1 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.